A large French cohort study finds that pregnant women with systemic sclerosis face increased risks of preeclampsia, preterm ...

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...

Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...

Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively ...

The report "Catalyst Monitor Q4 2025" highlights upcoming market opportunities in biotech and pharma, focusing on key approvals and trials such as Cytokinetics’s aficamten, Aldeyra’s reproxalap, and ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T ...

Distinct demographic, systemic sclerosis-specific, and cardiac factors are linked to a higher risk for left ventricular ...

At diagnosis, nailfold capillaroscopy findings — especially avascular areas — were independent predictors of major cardiovascular events and mortality in patients with systemic sclerosis (SSc), with ...

Please provide your email address to receive an email when new articles are posted on . Systemic sclerosis was associated with increased cancer risk compared with the general population. The study ...

The global systemic scleroderma treatment market expected to reach USD 2.2 billion by 2028 according to a new study by Report Ocean. The report “Systemic Scleroderma Treatment Market Report, By Drug ...

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.

Please provide your email address to receive an email when new articles are posted on . Patients with systemic sclerosis had increased risk for hematologic and solid organ cancers at 5 years vs. a ...